HCell

HCell is a private Austin, Texas biotechnology company focused on developing regenerative treatments for hair-loss disorders. The company appears to be primarily focused on alopecia areata, especially pediatric alopecia areata, and androgenetic alopecia. Publicly available descriptions indicate that its lead programs use proprietary biologic and autologous tissue-based approaches intended to promote hair regeneration. HCell has disclosed HC017AA, which received U.S. FDA orphan drug designation for pediatric alopecia areata in January 2018, and HC0100 for androgenetic alopecia. Based on the limited public record, the company remains early stage and there is no clear evidence of active clinical trials or a commercial product.